Pluri Inc. (PLUR)

NASDAQ: PLUR · IEX Real-Time Price · USD
0.807
-0.073 (-8.27%)
Mar 28, 2024, 10:56 AM EDT - Market open

Company Description

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.

It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.

The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.

It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.

Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Pluri Inc.
Pluri logo
Country Israel
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 123
CEO Yaacov Yanay

Contact Details

Address:
Matam Advanced Technology Park, Building No. 5
Haifa, L3 3508409
Israel
Phone 972-74-710-7171
Website pluri-biotech.com

Stock Details

Ticker Symbol PLUR
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001158780
CUSIP Number 72942G104
ISIN Number US72942G1040
Employer ID 98-0351734
SIC Code 2836

Key Executives

Name Position
Yaacov Yanay President, Chief Executive Officer and Director
Chen Franco-Yehuda Chief Financial Officer, Treasurer and Secretary
Lior Raviv Chief Technology Officer
Efrat Livne-Hadass Vice President of Human Resources
Dr. Nitsan Halevy M.D. Chief Medical Officer
Nimrod Bar Zvi Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 14, 2024 SCHEDULE 13G Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 424B5 Filing
Feb 13, 2024 8-K Current Report
Feb 12, 2024 10-Q Quarterly Report
Feb 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 29, 2024 SCHEDULE 13G Filing
Jan 24, 2024 8-K Current Report
Jan 8, 2024 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report